Key Points
- Grigorios Siokas, CEO of Cosmos Health, bought 353,321 shares on January 20 at $0.50 per share for a total of $176,660.50, bringing his total holdings to 8,091,795 shares.
- Siokas has been an active buyer since November–January with multiple insider purchases (including 493,495 shares on January 14), cumulatively increasing his stake in the company.
- Shares traded up ~5% on the news; Cosmos Health has a market cap of about $19.46 million, reported negative EPS and margins, and carries a consensus analyst rating of Sell.
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 353,321 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were purchased at an average cost of $0.50 per share, with a total value of $176,660.50. Following the completion of the transaction, the chief executive officer owned 8,091,795 shares in the company, valued at approximately $4,045,897.50. The trade was a 4.57% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Grigorios Siokas also recently made the following trade(s):
- On Wednesday, January 14th, Grigorios Siokas bought 493,495 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.45 per share, for a total transaction of $222,072.75.
- On Monday, January 12th, Grigorios Siokas purchased 113,185 shares of Cosmos Health stock. The stock was acquired at an average price of $0.50 per share, for a total transaction of $56,592.50.
- On Thursday, January 8th, Grigorios Siokas purchased 156,190 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.52 per share, with a total value of $81,218.80.
- On Wednesday, January 7th, Grigorios Siokas acquired 124,880 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.52 per share, with a total value of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas acquired 133,953 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.54 per share, with a total value of $72,334.62.
- On Friday, December 19th, Grigorios Siokas bought 88,314 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.49 per share, for a total transaction of $43,273.86.
- On Monday, December 15th, Grigorios Siokas bought 168,472 shares of Cosmos Health stock. The shares were acquired at an average price of $0.42 per share, with a total value of $70,758.24.
- On Friday, November 28th, Grigorios Siokas purchased 76,360 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.64 per share, with a total value of $48,870.40.
- On Tuesday, November 25th, Grigorios Siokas acquired 55,732 shares of Cosmos Health stock. The shares were bought at an average cost of $0.63 per share, for a total transaction of $35,111.16.
- On Friday, November 21st, Grigorios Siokas acquired 56,080 shares of Cosmos Health stock. The shares were bought at an average price of $0.68 per share, with a total value of $38,134.40.
Cosmos Health Trading Up 5.0%
Shares of Cosmos Health stock opened at $0.52 on Thursday. The company has a current ratio of 0.99, a quick ratio of 0.84 and a debt-to-equity ratio of 0.25. The company has a fifty day simple moving average of $0.54 and a 200-day simple moving average of $0.73. The stock has a market cap of $19.46 million, a price-to-earnings ratio of -0.69 and a beta of 5.37. Cosmos Health Inc. has a 12-month low of $0.28 and a 12-month high of $1.32.
Cosmos Health (NASDAQ:COSM - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.16). Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%.The company had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.40 million. On average, equities analysts forecast that Cosmos Health Inc. will post -0.78 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cosmos Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of "Sell".
Get Our Latest Stock Report on Cosmos Health
Institutional Investors Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC increased its stake in shares of Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 225,507 shares of the company's stock after buying an additional 128,776 shares during the quarter. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 at the end of the most recent quarter. 12.61% of the stock is currently owned by institutional investors and hedge funds.
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
